Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Avian Flu Treatment Market Size Forecast: How Big Could The Market Get By 2030?
The avian flu treatment market has demonstrated substantial growth in recent years. It is anticipated to expand from $13.77 billion in 2025 to reach $15.04 billion in 2026, with a compound annual growth rate (CAGR) of 9.3%. This historical growth is primarily attributable to factors such as a rise in avian influenza outbreaks, the implementation of antiviral stockpiling strategies, government-led initiatives for disease control, the expansion of hospital-based infectious disease treatment options, and increased public health awareness.
The avian flu treatment market is projected to experience substantial expansion in the coming years. This market is forecast to reach $20.6 billion by 2030, demonstrating an 8.2% compound annual growth rate (CAGR). Factors contributing to this growth during the forecast period include greater financial commitments to zoonotic disease research, the ongoing development of advanced vaccines, the broadening of worldwide disease surveillance systems, an increased emphasis on fast-acting therapeutics, and enhanced global cooperation for pandemic readiness. Key trends anticipated for this period involve a wider uptake of sophisticated antiviral treatments, a heightened concentration on platforms for quick vaccine development, the increasing application of monoclonal antibody therapies, the expansion of programs for early detection and monitoring, and a reinforced commitment to pandemic preparedness strategies.
Get A Free Sample Report With In-Depth Market Insights:
Avian Flu Treatment Market Growth Momentum: What Factors Are Shaping Demand?
Increasing recognition and identification of avian flu are anticipated to fuel the expansion of the avian flu treatment market in the future. Awareness refers to acknowledging a health condition, whereas diagnosis involves pinpointing a particular problem stemming from that awareness. The necessity for avian flu treatment stems from the critical need to preserve public health, avert possible pandemics, and shield poultry from substantial financial impacts. Prompt recognition and timely diagnosis are vital for successful avian flu treatment, facilitating swift action and control measures to stop its propagation. For example, the World Health Organization (WHO), an intergovernmental body based in Switzerland, reported in April 2024 that over 8000 people in the US were actively monitored between February 9, 2022, and March 29, 2024, following exposure to animals suspected of carrying the HPAI A (H5N1) virus. Consequently, heightened awareness and improved diagnosis are stimulating growth within the avian flu treatment market.
Avian Flu Treatment Market Segment Analysis: What Are The Core Market Categories?
The avian flu treatment market covered in this report is segmented –
1) By Type: Vaccines, Antiviral Agents, Immunoglobulins
2) By Distribution Channel: Online Pharmacies, Offline Pharmacies
3) By End User: Hospital, Institutional Health Centers, Clinics
Subsegments:
1) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Subunit Vaccines, Dna Vaccines, Bivalent And Multivalent Vaccines
2) By Antiviral Agents: Neuraminidase Inhibitors (Oseltamivir, Zanamivir), Polymerase Inhibitors, Antiviral Combination Therapies
3) By Immunoglobulins: Human Immunoglobulin (Ivig), Monoclonal Antibodies, Hyperimmune Serum, Polyvalent Immunoglobulins, Avian Flu-Specific Immunoglobulins
Avian Flu Treatment Market Trends Redefining Industry Growth
Leading firms within the avian flu treatment sector are concentrating on forging collaborations to improve effectiveness and accelerate the progress of novel therapies. These alliances encompass joint efforts among drug manufacturers, scientific bodies, and state entities to combine assets, exchange knowledge, and carry out advanced clinical studies. As an illustration, during April 2024, CureVac N.V., a biotechnology enterprise located in Germany, collaborated with GSK plc, a pharmaceutical firm based in the UK, to develop an experimental influenza A (H5N1) pre-pandemic vaccine candidate aimed at confronting the prospective future pandemic risk presented by the H5N1 avian influenza virus. The objective of this joint venture is to assess the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which codes for an influenza A H5 antigen utilizing CureVac’s unique second-generation mRNA backbone. The integrated Phase 1/2 investigation will evaluate the safety and efficacy of the vaccine candidate in healthy adults ranging from 18 to 64 years old, along with elderly individuals between 65 and 85 years old.
Avian Flu Treatment Market Top Companies Driving Competitive Growth
Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited
View The Full Avian Flu Treatment Market Report:
Avian Flu Treatment Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









